Analystreport

vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $49.00 price target on the stock, up previously from $40.00.

vTv Therapeutics Inc. - Class A  (VTVT) 
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vtvtherapeutics.com